NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an ...

We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Harrow, Inc. is one of them. Harrow, Inc. (NASDAQ:HROW), a leading U.S.-based pharmaceutical company, is ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2024. The ...

Please provide your email address to receive an email when new articles are posted on . Byooviz references Lucentis, and Opuviz references Eylea. Harrow expects the transaction to be completed by the ...

Please provide your email address to receive an email when new articles are posted on . Harrow plans to submit a new drug application in 2027 for sublingual MELT-300 for sedation and analgesia.